Multiple sclerosis, rituximab, and COVID‐19-Reference-Cited by-同舟云学术

Multiple sclerosis, rituximab, and COVID‐19

Published:2021-03-30 Issue:4 Volume:8 Page:938-943
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann. Clin. Transl. Neurol.

Author:

Langer‐Gould Annette¹^ORCID,Smith Jessica B.²,Li Bonnie H.²,Beaber Brandon E,Brara Sonu M,Debacker Julie,Nielsen Allen Scott,Amirova Samira,Ayeni Oluwasheyi,

Affiliation:

1. Department of Neurology Los Angeles Medical CenterSouthern California Permanente Medical Group Los Angeles CAUSA

2. Department of Research & Evaluation Southern California Permanente Medical Group Pasadena CAUSA

Funder

Patient-Centered Outcomes Research Institute

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acn3.51342

Reference19 articles.

1. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

2. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

3. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

4. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain

5. COVID-19 outcomes in MS

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders;Vaccine;2024-10

2. Clinical features of COVID-19 infection in patients with myasthenia gravis: a real-world retrospective study;Frontiers in Public Health;2024-08-27

3. Low-dose rituximab regimen does not increase severe COVID-19 risk in patients with neuroimmune diseases during the pandemic: a cross-sectional study;2024-07-29

4. De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis;Current Neurology and Neuroscience Reports;2024-07-12

5. COVID-19 Infection in Multiple Sclerosis Patients Treated with Rituximab Compared to Natalizumab and Healthy Controls: A Real-World Multicenter Study;Annals of Indian Academy of Neurology;2024-05